Links to Sources of Depression Info & Support
Here is a useful list of depression resources that provide advocacy, information, and support for patients, families and caregivers.
Substance Abuse and Mental Health Services Administration (SAMHSA)
Utilizing its sub-division, The Center for Mental Health Services, SAMSHA supports efforts to prevent the development or worsening of depression, other psychiatric conditions, and substance abuse by helping provide services for people with mental illness, and their families and communities.
Depression and Bipolar Support Alliance (DBSA)
Formerly called the National Depression and Manic Depression Association, the DBSA offers local and on-line support groups along with information, podcasts and other resources for people living with Depression or Bipolar Disorder.
National Alliance on Mental Illness (NAMI)
NAMI is the nation's largest patient/family advocacy and support organization for depression and other psychiatric conditions. Active local chapters and a national hot line provide multiple channels of support and information services for patients and families, including information on medications.
Mental Health America (NMHA)
Formerly known as the National Mental Health Association, this group is the nation's oldest Mental Health Advocacy organization (founded in 1909). They provide Mental Health Awareness information and advocacy and support services and are the sponsors of the annual National Depression Screening Day.
National Suicide Prevention Lifeline
This confidential lifeline service for patients contemplating suicide immediately routes callers to one of 140 local intervention centers where they can talk to trained crisis workers in their area. Family members are also welcome to use these resources.
Please see Full Prescribing Information including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO Inhibitors are contraindicated with certain drugs. Potential hypertensive crises may occur with foods that contain tyramine. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of treatment.
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Marplan® (isocarboxazid) Tablets or any other antidepressant in a child, adolescent or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Marplan® (isocarboxazid) Tablets is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use).
Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials.